



SUGGESTED READING

Session 1

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures.

Anderson JA, et al. JACC. Volume 63, Issue 21, June 2014. [PMID: 24681044](#)

Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach.

Gallagher AM, et al. ESC Heart Fail. 2019;6(1):3-9. [PMID: 30311454](#)

Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Garin O, et al. Heart Fail Rev. 2014;19(3):359-367. [PMID: 23681849](#)

Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. Sepehrvand N, et al. [J Am Heart Assoc](#). 2020;e017278.

Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes. Yee D, et al. Am J Cardiol. 2019;123(5):807-812. [PMID: 30587373](#)

Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. McEwan P, et al. Eur J Heart Fail. 2020 Aug 4. [PMID: 32749733](#)

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. McMurray JJV, et al. N Engl J Med. 2019 Nov 21;381(21):1995-2008. [PMID: 31535829](#)

Does heart failure-specific health status identify patients with bothersome symptoms, depression, anxiety, and/or poorer spiritual well-being? Flint KM, et al. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):233-241. [PMID: 30649237](#)

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Solomon SD, et al. JACC Heart Fail. 2020 Jul 8:S2213-1779(20)30254-7. [PMID: 32653447](#)

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Petrie MC, et al. JAMA. 2020 Mar 27;323(14):1353-68. [PMID: 32219386](#)

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Kosiborod MN, et al. Circulation. 2020 Jan 14;141(2):90-99. [PMID: 31736335](#)

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Vaduganathan M, et al. Lancet. 2020 Jul 11;396(10244):121-128. [PMID: 32446323](#)

Evaluating Pharmacist Impact on Guideline-Directed Medical Therapy in Patients With Reduced Ejection Fraction Heart Failure. Ingram A, et al. J Pharm Pract. 2019;897190019866930. [PMID: 31401924](#)

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Packer M, et al. Eur J Heart Fail. 2019 Oct;21(10):1270-1278. [PMID: 31584231](#)



Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Heidenreich PA, et al. *Circ Heart Fail.* 2013 May;6(3):606-19. [PMID: 23616602](#)

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. Khariton Y, et al. *JACC Heart Fail.* 2018;6(6):465-473. [PMID: 29852931](#)

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Chandra A, et al. *JACC Heart Fail.* 2019;7(10):862-874. [PMID: 31302043](#)

Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. Bhagat AA, et al. *JACC Heart Fail.* 2019;7(1):1-12. [PMID: 30414818](#)

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. Greene SJ, et al. *J Am Coll Cardiol.* 2018;72(4):351-366. [PMID: 30025570](#)

Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Butler J, et al. *Eur J Heart Fail.* 2020;22(6):999-1005. [PMID: 32239794](#)

Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. Januzzi JL Jr, et al. *J Am Coll Cardiol.* 2019;74(9):1205-1217. [PMID: 31466618](#)

Optimisation of diagnosis and treatment of heart failure in a primary care setting. Bakhai S, et al. *BMJ Open Qual.* 2019;8(4):e000660. Published 2019 Oct 14. [PMID: 31673640](#)

Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. Samsky MD, et al. *JAMA Cardiol.* 2019;5(3). [PMID: 31734700](#)

Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. Vardeny O and Vaduganathan M. *JACC Heart Fail.* 2019 Feb;7(2):169-172. [PMID: 30704605](#)

Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. Blood AJ, et al. *Clin Cardiol.* 2020;43(1):4-13. [PMID: 31725920](#)

The Break-Even Point: When Medical Advances Are Less Important Than Improving the Fidelity With Which They Are Delivered. Woolf S and Johnson R. *Ann Fam Med.* Nov-Dec 2005;3(6):545-52. [PMID: 16338919](#)

The Cost-Effectiveness of Digital Health Interventions on the Management of Cardiovascular Diseases: Systematic Review. Jiang X. *J Med Internet Res.* 2019 Jun 17;21(6):e13166. [PMID: 31210136](#)

The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. Nieminen MS, et al. *Int J Cardiol.* 2015;191:256-264. [PMID: 25981363](#)



Session 2

African Americans Are Less Likely to Receive Care by a Cardiologist During an Intensive Care Unit Admission for Heart Failure. Breathett K, et al. JACC Heart Fail 2018;6:413–420. [PMID: 29724363](#)

American Heart Association's Life's Simple 7: Avoiding Heart Failure and Preserving Cardiac Structure and Function. Folsom AR, et al. Am. J. Med. 2015;128:970-976.e2. [PMID: 25908393](#)

Association of Gender and Race with Allocation of Advanced Heart Failure Therapies. Breathett K, et al. JAMA Netw Open 2020;3:e2011044. [PMID: 32692370](#)

Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. Chan PS, et al. J. Am. Coll. Cardiol. 2010;56:8–14. [PMID: 20620710](#)

Disparities in Cardiovascular Mortality Related to Heart Failure in the United States. Glynn P, et al. Journal of the American College of Cardiology 2019;73:2354–2355. [PMID: 31072580](#)

Does Race Influence Decision Making for Advanced Heart Failure Therapies? Breathett K, et al. J Am Heart Assoc 2019;8:e013592. [PMID: 31707940](#)

Ethnic and racial disparities in cardiac resynchronization therapy. Farmer SA, et al. Heart Rhythm 2009;6:325–331. [PMID: 19251206](#)

Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis. Breathett K, et al. J Racial Ethn Health Disparities 2018;5:1215–1229. [PMID: 29508374](#)

Heart Disease and Stroke Statistics—2020 Update. Virani S, et al. Circulation 0:CIR.0000000000000757. [PMID: 31992061](#)

Heart Failure in Hispanics. Vivo RP, et al. J Am Coll Cardiol 2009;53:1167–1175. [PMID: 19341856](#)

Heart Failure in Women: Epidemiology, Biology and Treatment. Shah RU, et al. Womens Health (Lond Engl) 2009;5:517–527. [PMID: 19702451](#)

INTERMACS Quarterly Statistical Report 2015 Q1 Implant and event dates: June 23, 2006 to March 31, 2015. Interagency Registry for Mechanically Assisted Circulatory Support: The Data and Clinical Coordinating Center University of Alabama at Birmingham; 2015:32. Available at: https://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Federal_Partners_Report_2015_Q1.pdf.

OPTN/SRTR 2018 Annual Data Report: Heart. Colvin M, et al. American Journal of Transplantation 2020;20:340–426. [PMID: 31898418](#)

Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. Yancy CW, et al. J. Am. Coll. Cardiol. 2008;51:1675–1684. [PMID: 18436120](#)

Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. Sullivan LT, et al. American Heart Journal 2018;197:43–52. [PMID: 29447783](#)



Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups: Insights From the Women's Health Initiative. Breathett K, et al. *Circ Heart Fail* 2018;11:e004642. [PMID: 29716899](#)

Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. Breathett K, et al. *Circulation: Heart Failure* 2018;11:e005008. [PMID: 30021796](#)

Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005–2014). Chang P, et al. *Circulation* 2018;138:12–24. [PMID: 29519849](#)

Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients. Nayak Aditi, et al. *Circulation: Heart Failure* 2020;13:e007264. [PMID: 32787445](#)

Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (with CD). Smedley B, et al. Institute of Medicine; 2003. Available at: <https://download.nap.edu/openbook.php?isbn=030908265X>.

Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. Jin X, et al. *Circulation* 2020;141:540–548. [PMID: 32065763](#)